Aims Expression and activation of matrix metalloproteinase (MMP)-2 play pivotal roles in the migration and invasion of human aortic vascular smooth muscle cells (VSMC) originating from normal human tissue, which is strongly linked to atherosclerosis. The present study investigated the possible inhibitory effects of cocoa procyanidin on thrombin-induced expression and activation of MMP-2 in VSMC. Methods and results Cocoa procyanidin fraction (CPF) and procyanidin B2, one of major procyanidins in cocoa (3 mg/mL and 5 mM, respectively), strongly inhibited thrombin-induced activation and expression of pro-MMP-2 in VSMC, as determined by zymography. The thrombin-induced invasion and migration of VSMC were inhibited by CPF or procyanidin B2 (P , 0.05), as assessed by a modified Boyden chamber and wound healing assays, respectively. An enzymatic assay data demonstrated that CPF and procyanidin B2 directly inhibited membrane type-1 (MT1)-MMP activity (P , 0.05), and this inhibition of CPF was greater than those of red wine polyphenols. Western blot data showed that CPF and procyanidin B2 inhibited thrombin-induced phosphorylation of extracellular signal-regulated protein kinase but not mitogen-activated protein kinase kinase (MEK) in VSMC. Kinase and pull-down data revealed that CPF and procyanidin B2 inhibited MEK1 activity and directly bound with glutathione-S-transferase-MEK1. In addition, the thrombin-induced invasion and migration and the activation and expression of pro-MMP-2 in VSMC were attenuated by U0126 (a well-known inhibitor of MEK1). Conclusion Cocoa procyanidins are potent inhibitors of MEK and MT1-MMP, and subsequently inhibit the expression and activation of pro-MMP-2, and also the invasion and migration of VSMC, which may in part explain the molecular action of antiatherosclerotic effects of cocoa.
Introduction
The development of atherosclerotic lesions is characterized by excessive vascular remodelling with accumulation of cells and lipids within the intimal layer of the pathological artery. 1 The structural reorganization of the blood vessel wall during atherogenesis is controlled by matrix metalloproteinases (MMPs), which degrade most of the extracellular matrix (ECM). 1, 2 The essential members of this family in human vascular smooth muscle cells (VSMC) are the gelatinases MMP-2 and MMP-9, 2 which are thought to be major
MMPs that degrade most collagens in human atherosclerotic plaques. 2 MMP-2 is expressed as a latent zymogen, pro-MMP-2, by VSMC, endothelial cells, and macrophages, and is activated by membrane type MMPs (MT-MMPs), 2,3 especially MT1-MMP (which is also the most studied). Thus, gelatinases are likely to play an important role in atherosclerotic remodelling as well as in clinical complications of atherosclerosis (e.g. fissure and rupture) that lead to thrombosis by inducing a collagen-poor local environment.
Thrombin is a serine protease enzyme with different actions on blood cells and blood vessels. It regulates platelet aggregation, cascade coagulation, and VSMC activation. Previous studies have indicated that thrombin is a potent activator of pro-MMP-2 in VSMC and that this effect requires MT1-MMP activity in endothelial cells. 4 The mitogen-activated protein kinases (MAPKs) including extracellular-signal-regulated † These authors contributed equally to this work.
protein kinase (ERK) and p38 MAPK are present in the most common signalling pathways known to mediate activation or expression of MMP-2. 5 Recent studies have linked thrombin-stimulated migration of VSMC to reactive oxygen species (ROS) production and p38 MAPK activation. 6 It is also known that thrombin and activation of the ERK signalling pathway control MMP-2 expression in arterialized vein grafts. 5 MAPK kinase (MEK) is a dual-specificity protein kinase that phosphorylates its downstream target ERK on specific threonine and tyrosine residues. Although the proteins have some redundancy in function, the MEK/ERK signalling pathway generally plays a critical role in transmitting signals initiated by angiogenesis or atherosclerosis promoters such as thrombin, platelet-derived growth factor, and cytokines. 7, 8 However, there has been no report on whether the MEK/ERK signalling pathway is involved in thrombin-induced invasion and migration, and MMP-2 expression in VSMC.
Cocoa and chocolate are excellent sources of dietary phenolic substances, and their major phenolic phytochemicals are procyanidins. 9 Epidemiological studies suggested that cocoa consumption exerts beneficial effects on cardiovascular diseases and atherosclerosis. [10] [11] [12] A recent cohort study demonstrated that constant intake of cocoa can lower blood pressure and reduce the risk of cardiovascular diseases. 13 However, the underlying molecular mechanisms and molecular target(s) are poorly understood. In the present work, we studied the possible inhibitory effects of the procyanidin-rich fraction prepared from commercially available cocoa (cocoa procyanidin fraction, CPF) and the main procyanidin compound of cocoa, procyanidin B2, on thrombin-induced expression and activation of pro-MMP-2 using human VSMC.
Methods

Chemicals
Procyanidin B2 was purchased from Funakoshi. MCDB131, basal medium Eagle, streptomycin/penicillin, insulin, and L-glutamine were purchased from GIBCO BRL. Fetal bovine serum (FBS) was purchased from Gemini Bio-Products; and EGF and FGF were purchased from InVitrogen. The antibodies against phosphorylated MEK (Ser217/221), phosphorylated ERK (Thr202/Tyr204), and total ERK were purchased from Cell Signal Biotechnology. The antibodies against total MEK1 were purchased from Santa Cruz Biotechnology. 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) and the antibodies against b-actin and thrombin were purchased from Sigma Chemical. The MEK1 and MT1-MMP kit was obtained from Upstate Biotechnology and Amersham, respectively. CNBr-Sepharose 4B, glutathione-Sepharose 4B, and [g-32 P]ATP were purchased from Amersham Pharmacia Biotech, and the protein assay kit was obtained from Bio-Rad Laboratories.
Preparation of cocoa procyanidin fraction, red wine polyphenolic compounds, and green tea polyphenolic extract
The procedures used to prepare CPF, red wine polyphenolic comounds (RWPCs), and green tea polyphenol extract (GTE) have been described previously.
14-16
Determination of total flavonoid content
The total flavonoid content of CPF was measured by a colourimetric assay method developed by Zhishen et al. 17 The assay was performed in five replications for each sample. The total flavonoid content is expressed as milligrams per gram of epicatechin equivalent (ECE).
Cell culture
Human aortic VSMC originated from normal human tissue were obtained by permission according to the Declaration of Helsinki and supplied by BioWhittaker (Walkersville, USA). They were cultured in monolayers at 378C in a 5% CO 2 incubator in MCDB131 containing 10% FBS, 2 mM L-glutamine, EGF, bFGF, insulin, and streptomycin/penicillin. All experiments were performed with VSMC from passages 5 to 15.
Cell proliferation assay
To estimate cell proliferation, VSMC (1.5 Â 10 4 ) were seeded into 96-well plates and cultured for 24 h. The cells were treated with different concentrations of CPF (0-100 mg/mL), procyanidin B2 (0-100 mM), or U0126 (0-10 mM), and their viability was determined by reading the absorbance at 492 nm at 12-h intervals up to 48 h.
Gelatin zymographic assay for matrix metalloproteinases
) were plated on 6-well dishes and grown to 90% confluence in 2 mL of growth medium. The cells were maintained in serum-free medium for an additional 24 h with 2 U/mL thrombin alone or together with CPF, procyanidin B2, or U0126. Gelatin zymographic assay was performed as described in our previous study. 15 Areas of gelatinase activity were detected as clear bands against the blue-stained gelatin background.
Invasion assay
VSMC (5 Â 10 4 ) were resuspended with 2 U/mL thrombin alone or together with CPF, procyanidin B2, or U0126 in 100 mL of medium and placed in the upper part of the Transwell plate. The cells were then incubated for 24 h in a humidified atmosphere of 5% CO 2 at 378C. The ability of VSMCs to invade matrix was determined with a commercial cell invasion assay kit (Chemicon International) as described in our previous study. 15 
Wound migration assay
) were plated on 6-well dishes and grown to 90% confluence in 2 mL of growth medium. The cells were damaged using a 2-mm-wide tip. The cells were treated with 2 U/mL thrombin alone or together with CPF, procyanidin B2, or U0126. The cells were allowed to migrate, and photographs were taken through an inverted microscope (Â40 magnification).
MT1-MMP activity assay
A commercially available MT1-MMP activity assay kit (Amersham) was used for determining the MT1-MMP activity. In brief, solubilized membrane-bound MT1-MMP was bound to a specific antibody coating a 96-well microplate, and activity was assayed with a chromogenic peptide substrate.
Western blotting
After VSMC (1.5 Â 10 6 ) were cultured in a 10-cm-diameter dish for 48 h, they were starved in serum-free medium for another 24 h to eliminate the influence of FBS on the activation of kinases. The cells were then treated with CPF (0-30 mg/mL) or procyanidin B2 (0-50 mM) for 1 h before being exposed to 2 U/mL thrombin for 15 min. Western blot analysis was performed as described in our previous study.
MEK1 assay
The kinase assays were performed in accordance with the instructions provided by Upstate Biotechnology. The effects of CPF (0-30 mg/mL) and procyanidin B2 (0-30 mM) were evaluated by separately incubating each compound with the reaction mixtures at 308C for 30 min.
Pull-down assay
Recombinant MEK1 (2 mg) was incubated with CPF-Sepharose 4B (or Sepharose 4B alone as a control) beads (100 mL, 50% slurry) in reaction buffer comprising 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 150 mM NaCl, 1 mM DTT, 0.01% Nonidet P-40, 2 mg/mL BSA, 0.02 mM PMSF, and 1Â protease inhibitor mixture. After incubation with gentle rocking overnight at 48C, the beads were washed five times with buffer [50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 150 mM NaCl, 1 mM DTT, 0.01% Nonidet P-40, and 0.02 mM PMSF], and proteins bound to the beads were analyzed by immunoblotting.
Statistical analysis
Data are expressed as mean + SD values. One-way analysis of variance was used for comparisons in the experiments with multiple time points and concentrations. Probability value of P , 0.05 was used as the criterion for statistical significance.
Results
CPF and procyanidin B2 inhibit thrombin-induced expression and activation of pro-MMP-2 in vascular smooth muscle cells
CPF was extracted from commercial cocoa powder as described in our previous study and contained 413 mg/g ECE flavonoids. We first measured the viability of VSMC treated with CPF or procyanidin B2.
14 Treatment with CPF or procyanidin B2 (up to a concentration of 30 mg/mL or 50 mM, respectively) did not affect the viability of VSMC for 48 h ( Figure 1A and B) . We next examined the inhibitory effects of CPF or procyanidin B2 on thrombin-induced activation of pro-MMP-2 in VSMC. Thrombin activated pro-MMP-2 to MMP-2 in VSMC, and this was inhibited dosedependently by treatment with CPF at 1, 3, 10, and 30 mg/mL. CPF at 30 mg/mL also inhibited pro-MMP-2 expression without thrombin induction ( Figure 1C) . The thrombin-induced expression and activation of pro-MMP-2 in VSMC were significantly inhibited by procyanidin B2 even at a concentration of 5 mM, and procyanidin B2 at 50 mM also inhibited basal pro-MMP-2 expression without thrombin induction ( Figure 1D ). These results indicate that cocoa procyanidins have inhibitory effects on thrombinmediated activation and expression of MMP-2 in VSMC.
CPF and procyanidin B2 attenuate thrombin-induced invasion and migration of vascular smooth muscle cells
Previous study has suggested that expression and activation of MMP-2 play pivotal roles in the invasion and migration of VSMC, which are strongly linked to atherosclerosis. 18 We next examined whether the inhibition of MMP-2 by CPF and procyanidin B2 is involved in the inhibition of invasion and migration of VSMC. Treatment with CPF (at concentrations of 10 and 30 mg/mL) or procyanidin B2 (at concentrations of 10 and 30 mM) strongly inhibited the thrombin-induced invasion (Figure 2A and B) and migration ( Figure 2C and D) of VSMC.
CPF and procyanidin B2 suppress thrombin-induced MT1-MMP activity in vascular smooth muscle cells
A previous study has shown that the thrombin-induced activation of MMP-2 on the cell surface is mediated by MT-MMPs, and especially by MT1-MMP in endothelial cells. 4 This suggests that the inhibitory effects of CPF and procyanidin B2 on thrombin-induced activation of pro-MMP-2 are related to MT1-MMP. Thus, we next examined whether CPF and procyanidin B2 directly inhibited MT1-MMP activity. The data revealed that thrombin increased the activity of MT1-MMP in VSMC, and this was effectively suppressed by CPF or procyanidin B2 ( Figure 3A and B) . In particular, MT1-MMP activity was inhibited more strongly by CPF than by RWPC. The inhibitory activity of CPF on MT1-MMP activity was similar to that of GTE ( Figure 3C ).
CPF and procyanidin B2 inhibit thrombin-induced phosphorylation of ERK but not that of MEK in vascular smooth muscle cells
Recent studies have shown that ERK is strongly involved in thrombin-induced MMP-2 activation in human coronary artery smooth muscle cells, 5 and that p38 MAPK is strongly involved in thrombin-induced migration of VSMC. 6 Thus, we next investigated the effect of CPF on the ERK and p38 MAPK signalling pathway, and found that CPF suppressed thrombin-induced phosphorylation of ERK in VSMC ( Figure  4A ). However, CPF had no effect on thrombin-induced phosphorylation of p38 MAPK in VSMC ( Figure 4A) . Similarly, procyanidin B2 suppressed thrombin-induced phosphorylation of ERK in VSMC ( Figure 4B) . Importantly, CPF and procyanidin B2 did not inhibit thrombin-induced phosphorylation of MEK, an upstream kinase of ERK, indicating that MEK may be a molecular target responsible for the inhibitory effects of CPF and procyanidin B2 on thrombin-induced phosphorylation of ERK in VSMC ( Figure 4A and B) .
3.5 CPF and procyanidin B2 suppress MEK1 activity, and directly bind with MEK1
We next investigated the effects of CPF and procyanidin B2 on MEK1 activity to determine whether MEK1 is a target of CPF and procyanidin B2. The data indicated that both CPF and procyanidin B2 strongly suppressed MEK1 activity in a dose-dependent manner ( Figure 5A and B) , indicating that the inhibition of MMP-2 expression by CPF and procyanidin B2 is associated with the suppression of MEK1 activity and its downstream ERK signalling pathway. To further confirm whether CPF and procyanidin B2 directly interact with MEK1, we next performed pull-down assays with CPF and procyanidin B2. The data revealed that MEK1 bound to CPF-Sepharose 4B beads ( Figure 5C, lane 3) and to procyanidin B2-Sepharose 4B beads ( Figure 5D, lane 3) , but not to Sepharose 4B beads alone ( Figure 5C and D, lane 2) , indicating that MEK1 could directly bind with CPF or procyanidin B2. Overall, the results indicate that MEK1 may be an important target molecule of CPF and procyanidin B2 for the inhibition of thrombin-induced cell invasion and migration, and MMP-2 expression. Inhibition of MEK1 and MT1-MMP by cocoa procyanidin 3.6 Activation of MEK is required for thrombin-induced expression and activation of pro-MMP-2, and invasion and migration of vascular smooth muscle cells
Since CPF and procyanidin B2 inhibited the phosphorylation of ERK via binding with MEK1, we further investigated the functional role of MEK activation in the thrombin-induced invasive and migrative phenotypes of VSMC using U0126, which is a specific inhibitor of MEK. The thrombin-induced increases in the invasion ( Figure 6A ) and migration ( Figure  6B ) of VSMC were reduced by treatment with U0126. The inhibitory effects of U0126 were not caused by its cytotoxicity because the concentration range used with U0126 did not affect cellular viability ( Figure 6C) . The thrombininduced expression and activation of pro-MMP-2 were also inhibited by U0126 at both 5 and 10 mM. U0126 at 10 mM inhibited basal pro-MMP-2 expression without thrombin induction ( Figure 6D) . These results confirm that activation of MEK is essential for thrombin-induced expression and activation of pro-MMP-2 in VSMC, which affects the invasive and migrative phenotypes of VSMC. These results support that MEK is a major molecular target of CPF for inhibiting invasion and migration, and the activation and expression of pro-MMP-2 in VSMC. (C) MT1-MMP was extracted from controls, RWPC-treated (followed by washing out) VSMC, or GTE-treated (followed by washing out) VSMC, and thereafter the activity of MT1-MMP was determined relative to controls in the absence or presence of RWPC, GTE or CPF (30 mg/ mL). Results are expressed as MT1-MMP activity relative to untreated controls. Data are mean + SD values. *P , 0.05 vs. untreated control. Figure 4 Effects of CPF and procyanidin B2 on thrombin-induced phosphorylation of MEK and ERK, and effects of CPF on thrombin-induced phosphorylation of p38 MAPK. (A) Cells were treated with 10 or 30 mg/mL CPF for 1 h, then stimulated with 2 U/mL thrombin and harvested 15 min later. The levels of phosphorylated ERK and total ERK, phosphorylated p38 MAPK and total p38 MAPK, and phosphorylated MEK and total MEK proteins were then determined by Western blot analysis. (B) Cells were treated with 10, 30, or 50 mM procyanidin B2 for 1 h, then stimulated with 2 U/mL thrombin and harvested 15 min later. The levels of phosphorylated MEK and total MEK, and phosphorylated ERK and total ERK were then determined by Western blot analysis. Data are representative of two independent experiments that gave similar results. Quantification of proteins (p-MEK, p-ERK, or p-p38) was normalized to total proteins (MEK, ERK, or p38) using a Sicon Image (NIH, Bethesda, MD).
Discussion
There are multiple lines of evidence that MMP-2 and MT1-MMP play pivotal roles in ECM degradation, and in the invasion and migration of VSMC. 3 Thrombin has been identified as a potential physiological inducer of the formation of MMP-2 in VSMC and endothelial cells. 19 Although the mechanisms of activation by thrombin remain unclear, in endothelial cells they are usually categorized as being either dependent on or independent of MT-MMP. 20 Thrombin markedly induces pro-MMP-2 activation in the presence of VSMC, and this effect is attributed to MT-MMP. Previous findings indicate that thrombin does not affect either the mRNA or protein expression levels of MT1-MMP. 15 Thrombin markedly increases cell-associated MT1-MMP activity in VSMC. Our data demonstrated that CPF and procyanidin B2 exerted a strong inhibitory effect on the thrombin-induced MT1-MMP activity in VSMC. Moreover, MT1-MMP is inhibited more strongly by CPF than by RWPC. The inhibitory activity of CPF on MT1-MMP activity is similar to that of GTE. These findings suggest that CPF and procyanidin B2 suppress the activation of pro-MMP-2 by directly inhibiting MT1-MMP activity, which may in part explain their inhibition of the invasive and migrative phenotypes of VSMC.
It is also known that the formation of MMP-2 requires the proteolytic activity of thrombin and involves a proteaseactivated receptor-independent mechanism in VSMC. A recent study has shown that the thrombin-induced migration of VSMC is linked to the generation of intracellular ROS by NADPH oxidase via p38 MAPK signals. 6 Inhibitors of NADPH oxidase and antioxidants suppress the phosphorylation of p38 MAPK and migration of VSMC. However, in the present study, CPF did not inhibit the thrombin-induced phosphorylation of p38 MAPK, which led us to predict that different mechanisms underlie the suppression of thrombin-induced migration of VSMC by CPF, independent of inhibiting the generation of ROS and the p38 MAPK signalling pathway. MEK1 and MEK2 exhibit 79% amino acid homology and are equally effective at phosphorylating ERK substrates. 21 No substrates for MEK1 have been identified other than ERK1 and ERK2, and activated MEK1 catalyzes the phosphorylation of ERK on both a threonine (Thr183) and a tyrosine (Tyr185) residue. 21 This tight selectivity, coupled with a unique ability to phosphorylate both threonine and tyrosine residues, indicates that this kinase is essential in integrating signals into the MAPK signalling pathway. The constitutive activation of MEK1 results in induction of angiogenesis and atherosclerosis, while a small-molecule inhibitor of MEK is capable of inhibiting angiogenesis and atherosclerosis in both cell culture and animal models. 5 CPF and procyanidin B2 bind to MEK1, inhibit its activity, and subsequently suppress phosphorylation of ERK. Our results also demonstrated that activation of MEK is required for the thrombin-induced expression and activation of pro-MMP-2, and in the invasion and migration of VSMC. Recent reports suggest that most of the mechanisms underlying antiatherosclerosis by phenolic phytochemicals are not related to their direct antioxidant activities but instead are due to the direct binding of the polyphenols to target molecules, including in the inhibition of selected protein kinases, MMPs, and cyclooxyenases. 15, 22 Our results support that the MEK1 is mainly responsible for the protective effects of CPF and procyanidin B2 on thrombin-induced expression and activation of pro-MMP-2 in VSMC. Inhibition of MEK1 and MT1-MMP by cocoa procyanidin Our recent study demonstrated that RWPC inhibited thrombin-induced invasion by directly inhibiting MT1-MMP activity in VSMC. 15 However, the compounds responsible for these effects of red wine are still unknown. We found that resveratrol (a well-known bioactive non-flavonoid compound in red wine) did not inhibit the thrombin-induced MT1-MMP activity (unpublished observation). The flavonoid content of red wines is dominated by oligomeric procyanidins, myricetin, and quercetin, with the content of resveratrol being much lower. Our results also suggest that flavonoids including procyanidin B2 may contribute to the inhibition of invasion and migration of VSMC treated with RWPC. Recent epidemiological studies suggested that a regular intake of cocoa exerts beneficial effects on cardiovascular diseases and atherosclerosis. [10] [11] [12] [13] Overall, the present study indicates that both CPF and procyanidin B2 inhibit the conversion of the inactive form pro-MMP-2 to the active form MMP-2, and that this is partially due to a direct inhibition of its physiological activator MT1-MMP. Both CPF and procyanidin B2 inhibited the expression of pro-MMP-2 by directly inhibiting MEK1, and may have contributed to inhibiting the invasion and migration of VSMC through the ECM degradation. It is notable that the inhibitory effects were significant when CPF and procyanidin B2 were used at low concentrations (1-3 mg/mL and 1-3 mM, respectively), with this level of procyanidin being considered achievable in the blood circulation after the oral ingestion of 80 g of black chocolate. 23, 24 Thus, our results might partially account for the chemoprotective effects of cocoa on cardiovascular diseases and atherosclerosis. 
